Bharat Biotech to have phase 3 efficacy data for Covaxin in 2 weeks

The restricted emergency use allowed by the regulator was based on phase 2 safety and immunogenicity studies, as well as data from monkey trials

Krishna Ella, chairman and managing director of Bharat Biotech, said the company would come out with the phase 3 efficacy data for Covaxin in two weeks. Speaking at a webinar, Ella said that had the company combined phase 2 and 3 studies, the efficacy data could have been available sooner.
 
Covaxin, the indigenous vaccine developed by Bharat Biotech and the Indian Council of Medical Research (ICMR), received a nod from the Indian drug regulator to be used to vaccinate health care and frontline workers, under clinical trial mode.
 
The restricted emergency use allowed by the regulator was based